SAN DIEGO, Feb. 1, 2010 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that Kirk Johnson, Ph.D. has joined MediciNova as its Chief Scientific Officer, reporting directly to Dr. Yuichi Iwaki, MediciNova’s President and Chief Executive Officer.
